Fusion Antibodies Ltd have announced a collaboration with Swiss biotech company Calypso Biotech for development of their CALY-002 Antibody.
The following is a press release from Fusion Antibodies.
The humanization program CALY-002 partnered with Fusion Antibodies relates to the in-licensing by Calypso Biotech of a monoclonal antibody from iDD Biotech, to be developed for treating Refractory Celiac Disease, a rare and devastating form of immune response to gluten.
Fusion Antibodies collaboration with Calypso Biotech is the latest in a series of successful Humanization projects. "We are delighted to be working with Calypso Biotech on such an exciting project and are enthusiastic to apply the Fusion Antibodies CDRx Humanization Platform to Calypso’s lead antibody and rapidly advance a high quality humanized antibody towards the clinic," says Paul Kerr, Managing Director of Fusion Antibodies.
Calypso Biotech SA is a spin-off company from Merck Serono, a division of Merck, Darmstadt, Germany, incorporated in March 2013 in Switzerland. Calypso Biotech discovers and develops antibodies for the treatment of gastrointestinal autoimmune diseases. "We are very confident that Fusion Antibodies will provide a high-quality humanized candidate in a time and resource-efficient manner for our CALY-002 program," says Alain Vicari, co-founder of Calypso Biotech.
The project is expected to progress over the summer with early results expected in the coming months.
About Fusion Antibodies
Fusion Antibodies; a UK based life science company, with innovative technologies and world-class expert services for antibody drug discovery, are specialists in production of High Quality Humanized Monoclonal Antibodies and Antibody Engineering Projects. With 10+ years of experience in the medical research industry, including two Antibodies in clinical and pre-clinical trials, Fusion Antibodies have extensive experience in accelerating therapeutic drug research towards the clinic.
Visit their website at www.fusionantibodies.com to find our more.